Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study.
Cze-Ci ChanKuang-Tso LeeWan-Jing HoYi-Hsin ChanPao-Hsien ChuPublished in: Annals of intensive care (2021)
Levosimendan did not increase short- or long-term mortality rates in critical patients with acute heart failure and reduced ejection fraction compared to dobutamine, regardless of their renal function. An eGFR less than 30 mL/min/1.73 m2 was not necessarily considered a contraindication for levosimendan in these patients.
Keyphrases
- acute heart failure
- heart failure
- cardiac surgery
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- acute kidney injury
- oxidative stress
- palliative care
- left ventricular
- tyrosine kinase
- type diabetes
- epidermal growth factor receptor
- early onset
- emergency department
- risk factors
- patient reported outcomes
- cardiovascular disease
- adverse drug
- atrial fibrillation
- coronary artery disease